Literature DB >> 16149213

[New methods for studying drug associated risk: experience of the Toulouse Regional Pharmacovigilance Center].

Jean-Louis Montastruc1, Haleh Bagheri, Isabelle Lacroix, Pascale Olivier, Genevieve Durrieu, Christine Damase-Michel, Maryse Lapeyre-Mestre.   

Abstract

This review examines the methods used to study adverse drug reactions (ADRs) and to quantify drug risk in pharmacovigilance. Beside analysis of spontaneous reports (the basic and universal alert method in pharmacovigilance), epidemiological methods can also be used. Classical methods are based on intensive recording, case-control or cohort studies, and clinical trials. Other more recent methods have been applied to pharmacovigilance. Using recent personal data, the authors present and discuss these new methods. Case/non-case studies quantify drug risk based on a pharmacovigilance database, and are used as signals in pharmacovigilance. Analysis of laboratory data can also be used to evaluate biological ADRs such as elevated liver enzyme and creatine phosphokinase levels. Cross-linkage studies can be used to minimize the consequences of under-notification in pharmacovigilance. Finally, ADR perception analysis is a useful method to evaluate the perceived social and medical importance of drug risks in different populations (public, pharmacists, general practitioners, medical specialists).

Mesh:

Year:  2005        PMID: 16149213

Source DB:  PubMed          Journal:  Bull Acad Natl Med        ISSN: 0001-4079            Impact factor:   0.144


  2 in total

1.  Safety of etanercept therapy in rheumatoid patients undergoing surgery: preliminary report.

Authors:  Salvatore Corrao; Giovanni Pistone; Sabrina Arnone; Luigi Calvo; Rosario Scaglione; Giuseppe Licata
Journal:  Clin Rheumatol       Date:  2007-01-17       Impact factor: 2.980

2.  Surgery during etanercept therapy in patients with rheumatoid arthritis: is it time to follow patient preferences?

Authors:  Salvatore Corrao; Giovanni Pistone; Sabrina Arnone; Luigi Calvo; Rosario Scaglione; Giuseppe Licata
Journal:  Intern Emerg Med       Date:  2008-02-13       Impact factor: 3.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.